All In Biotech

Drug Trial Radar · NCT05899049

A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, vs Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)-China Extension Study

An Open-label, Randomized Phase 3 Study to Evaluate Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or MK-1308A in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, as First-Line Treatment in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC)

Last checked: Nov 19, 2026Latest source record: Aug 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 251 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

251

Actual

Start

Jul 27, 2022

Primary completion

Feb 4, 2026

Study completion Apr 22, 2027

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
Collaborators
Eisai Inc.
First posted
Jun 12, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this China extension study is to evaluate the efficacy and safety of pembrolizumab plus belzutifan plus lenvatinib or pembrolizumab/quavonlimab plus lenvatinib versus pembrolizumab plus lenvatinib as first-line treatment in Chinese participants with advanced clear cell renal cell carcinoma (ccRCC). The primary hypotheses are (1) pembrolizumab plus belzutifan plus lenvatinib is superior to pembrolizumab plus lenvatinib with respect to progression-free survival (PFS) and overall survival (OS), in advanced ccRCC participants; and (2) pembrolizumab/quavonlimab plus lenvatinib is superior to pembrolizumab plus lenvatinib with respect to PFS and OS, in advanced ccRCC participants.

Conditions

  • Carcinoma, Renal Cell

Interventions

  • PembrolizumabBiological

    Pembrolizumab 400 mg administered Q6W via IV infusion

  • BelzutifanDrug

    Belzutifan 120 mg administered QD via oral tablet

  • Pembrolizumab/QuavonlimabBiological

    Pembrolizumab/quavonlimab is a co-formulated product composed of pembrolizumab 400 mg in combination with quavonlimab 25 mg, administered Q6W via IV infusion

  • LenvatinibDrug

    Lenvatinib 20 mg administered QD via oral capsule

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR)Time frame: Up to approximately 58 months
  2. Overall Survival (OS)Time frame: Up to approximately 58 months

Locations

17 sites in 1 country. Site status is shown where the registry gives one.

  • Beijing Cancer hospital-Renal carcinoma and melanoma ( Site 6000)

    Beijing, Beijing Municipality, China

  • Chongqing University Cancer Hospital ( Site 6009)

    Chongqing, Chongqing Municipality, China

  • SUN YAT-SEN UNIVERSITY CANCER CENTRE ( Site 6003)

    Guangzhou, Guangdong, China

  • The First Affiliated Hospital of Guangzhou Medical University-Urology ( Site 6036)

    Guangzhou, Guangdong, China

  • Guangzhou First People's Hospital ( Site 6007)

    Guangzhou, Guangdong, China

  • Henan Cancer Hospital-Urology ( Site 6006)

    Zhengzhou, Henan, China

  • Wuhan Union Hospital ( Site 6002)

    Wuhan, Hubei, China

  • Nanjing Drum Tower Hospital The Affiliated Hospital of Nanjing University Medical School-Urology ( S

    Nanjing, Jiangsu, China

  • The Second Affiliated Hospital of Soochow University-Urology ( Site 6025)

    Suzhou, Jiangsu, China

  • The First Affiliated Hospital of Nanchang University ( Site 6019)

    Nanchang, Jiangxi, China

  • The First Affiliated Hospital of Xi'an Jiaotong University ( Site 6014)

    Xi'an, Shaanxi, China

  • West China Hospital Sichuan University-Urology Surgery ( Site 6016)

    Chengdu, Sichuan, China

  • The Second Hospital of Tianjin Medical University ( Site 6032)

    Tianjin, Tianjin Municipality, China

  • The First Affiliated Hospital, Zhejiang University ( Site 6024)

    Hangzhou, Zhejiang, China

  • The First Hospital of Jiaxing ( Site 6033)

    Jiaxing, Zhejiang, China

  • Ningbo First Hospital-Urology ( Site 6028)

    Ningbo, Zhejiang, China

  • The First Affiliated Hospital of Wenzhou Medical University-Urology Surgery ( Site 6021)

    Wenzhou, Zhejiang, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.